The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Jul 2023
Meta AnalysisWhich patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Adding docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about who benefits most. We therefore aimed to obtain up-to-date estimates of the overall effects of docetaxel and to assess whether these effects varied according to prespecified characteristics of the patients or their tumours. ⋯ UK Medical Research Council and Prostate Cancer UK.